Nonalcoholic fatty liver disease: Update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine

Experimental Biology and Medicine

Volumn 240, Issue 6, 2015, Pages 809-820

  Noureddin, Mazen ^a   Mato, José M ^b   Lu, Shelly C ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b NONE   (Spain)

Author keywords

biomarkers; hepatocellular carcinoma; NASH; SAMe; treatment

Indexed keywords

ALPHA TOCOPHEROL; GLYCINE METHYLTRANSFERASE; METFORMIN; OBETICHOLIC ACID; PENTOXIFYLLINE; PIOGLITAZONE; S ADENOSYLMETHIONINE; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID; BIOLOGICAL MARKER; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE;

ARTICLE; FATTY LIVER; FOLLOW UP; HUMAN; HYPERINSULINEMIA; LIPID STORAGE; LIVER BIOPSY; LIVER CELL CARCINOMA; NONALCOHOLIC FATTY LIVER; SENSITIVITY AND SPECIFICITY; ANIMAL; DISEASE MODEL; LIVER; METABOLISM; MOUSE; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; UNITED STATES;

ANIMALIA; MUS;

ANIMALS; BIOMARKERS; DISEASE MODELS, ANIMAL; HUMANS; LIVER; MICE; NON-ALCOHOLIC FATTY LIVER DISEASE; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLETHANOLAMINES; S-ADENOSYLMETHIONINE; UNITED STATES;

EID: 84930815604     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370215579161     Document Type: Article

References (111)

1. Williams CD,Stengel J,Asike MI,Torres DM,Shaw J,Contreras M,Landt CL,Harrison SA.Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.Gastroenterology. 2011;140:124-31
2. LaBrecque DR,Abbas Z,Anania F,Ferenci P,Khan AG,Goh KL,Hamid SS,Isakov V,Lizarzabal M,Penaranda MM,Ramos JF,Sarin S,Stimac D,Thomson AB,Umar M,Krabshuis J,LeMair A.Review Team. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.J Clin Gastroenterol. 2014;48:467-73
3. Younossi ZM,Stepanova M,Afendy M,Fang Y,Younossi Y,Mir H,Srishord M.Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.Clin Gastroenterol Hepatol. 2011;9:524-30
4. Review T,LaBrecque DR,Abbas Z,Anania F,Ferenci P,Khan AG,Goh KL,Hamid SS,Isakov V,Lizarzabal M,Penaranda MM,Ramos JF,Sarin S,Stimac D,Thomson AB,Umar M,Krabshuis J,LeMair A.World Gastroenterology Organisation global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.J Clin Gastroenterol. 2014;48:467-73
5. Hamaguchi M,Kojima T,Takeda N,Nakagawa T,Taniguchi H,Fujii K,Omatsu T,Nakajima T,Sarui H,Shimazaki M,Kato T,Okuda J,Ida K.The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.Ann Intern Med. 2005;143:722-8
6. Park SH,Jeon WK,Kim SH,Kim HJ,Park DI,Cho YK,Sung IK,Sohn CI,Keum DK,Kim BI.Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults.J Gastroenterol Hepatol. 2006;21:138-43
7. Fan JG,Farrell GC.Epidemiology of non-alcoholic fatty liver disease in China.J Hepatol. 2009;50:204-10
8. Chen CH,Huang MH,Yang JC,Nien CK,Yang CC,Yeh YH,Yueh SK.Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults.J Clin Gastroenterol. 2006;40:745-52
9. Tsai CH,Li TC,Lin CC.Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease.South Med J. 2008;101:900-5
10. Mohan V,Farooq S,Deepa M,Ravikumar R,Pitchumoni CS.Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome.Diabetes Res Clin Pract. 2009;84:84-91
11. Dassanayake AS,Kasturiratne A,Rajindrajith S,Kalubowila U,Chakrawarthi S,De Silva AP,Makaya M,Mizoue T,Kato N,Wickremasinghe AR,de Silva HJ.Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population.J Gastroenterol Hepatol. 2009;24:1284-8
12. Wong VW,Chu WC,Wong GL,Chan RS,Chim AM,Ong A,Yeung DK,Yiu KK,Chu SH,Woo J,Chan FK,Chan HL.Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography.Gut. 2012;61:409-15
13. Ruhl CE,Everhart JE.Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States.Gastroenterology. 2003;124:71-9
14. Clark JM,Brancati FL,Diehl AM.The prevalence and etiology of elevated aminotransferase levels in the United States.Am J Gastroenterol. 2003;98:960-7
15. Browning JD,Szczepaniak LS,Dobbins R,Nuremberg P,Horton JD,Cohen JC,Grundy SM,Hobbs HH.Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.Hepatology. 2004;40:1387-95
16. Flegal KM,Carroll MD,Ogden CL,Curtin LR.Prevalence and trends in obesity among US adults, 1999–2008.JAMA. 2010;303:235-41
17. Flegal KM,Carroll MD,Kit BK,Ogden CL.Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010.JAMA. 2012;307:491-7
18. Charlton MR.Fibrosing NASH: on being a blind man in a dark room looking for a black cat (that isn't there).Gastroenterology. 2011;140:25-8
19. Chalasani N,Younossi Z,Lavine JE,Diehl AM,Brunt EM,Cusi K,Charlton M,Sanyal AJ.The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.Hepatology. 2012;55:2005-23
20. Rinella ME,Loomba R,Caldwell SH,Kowdley K,Charlton M,Tetri B,Harrison SA.Controversies in the diagnosis and management of NAFLD and NASH.Gastroenterol Hepatol. 2014;10:219-27
21. Mato JM,Lu SC.Where are we in the search for noninvasive nonalcoholic steatohepatitis biomarkers?.Hepatology. 2011;54:1115-7
22. Browning JD,Horton JD.Molecular mediators of hepatic steatosis and liver injury.J Clin Investig. 2004;114:147-52
23. Cohen JC,Horton JD,Hobbs HH.Human fatty liver disease: old questions and new insights.Science. 2011;332:1519-23
24. Hassan K,Bhalla V,El Regal ME,HH AK.Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic.World J Gastroenterol. 2014;20:12082-101
25. Kawaguchi T,Takenoshita M,Kabashima T,Uyeda K.Glucose and cAMP regulate the L-type pyruvate kinase gene by phosphorylation/dephosphorylation of the carbohydrate response element binding protein.Proc Natl Acad Sci USA. 2001;98:13710-5
26. Horton JD,Shah NA,Warrington JA,Anderson NN,Park SW,Brown MS,Goldstein JL.Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes.Proc Natl Acad Sci USA. 2003;100:12027-32
27. Noga AA,Zhao Y,Vance DE.An unexpected requirement for phosphatidylethanolamine N-methyltransferase in the secretion of very low density lipoproteins.J Biol Chem. 2002;277:42358-65
28. Fabbrini E,Mohammed BS,Magkos F,Korenblat KM,Patterson BW,Klein S.Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease.Gastroenterology. 2008;134:424-31
29. Fromenty B,Robin MA,Igoudjil A,Mansouri A,Pessayre D.The ins and outs of mitochondrial dysfunction in NASH.Diabet Metabol. 2004;30:121-38
30. Sunny NE,Parks EJ,Browning JD,Burgess SC.Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease.Cell Metabol. 2011;14:804-10
31. Hui JM,Hodge A,Farrell GC,Kench JG,Kriketos A,George J.Beyond insulin resistance in NASH: TNF-alpha or adiponectin?.Hepatology. 2004;40:46-54
32. Puri P,Mirshahi F,Cheung O,Natarajan R,Maher JW,Kellum JM,Sanyal AJ.Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease.Gastroenterology. 2008;134:568-76
33. Neuschwander-Tetri BA,Caldwell SH.Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference.Hepatology. 2003;37:1202-19
34. Sanyal AJ,Brunt EM,Kleiner DE,Kowdley KV,Chalasani N,Lavine JE,Ratziu V,McCullough A.Endpoints and clinical trial design for nonalcoholic steatohepatitis.Hepatology. 2011;54:344-53
35. Noureddin M,Loomba R.Nonalcoholic fatty liver disease: Indications for liver biopsy and noninvasive biomarkers.Clin Liver Dis. 2012;1:104-7
36. Neuschwander-Tetri BA,Clark JM,Bass NM,Van Natta ML,Unalp-Arida A,Tonascia J,Zein CO,Brunt EM,Kleiner DE,McCullough AJ,Sanyal AJ,Diehl AM,Lavine JE,Chalasani N,Kowdley KV.Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.Hepatology. 2010;52:913-24
37. Ratziu V,Charlotte F,Heurtier A,Gombert S,Giral P,Bruckert E,Grimaldi A,Capron F,Poynard T.Sampling variability of liver biopsy in nonalcoholic fatty liver disease.Gastroenterology. 2005;128:1898-906
38. Hernaez R,Lazo M,Bonekamp S,Kamel I,Brancati FL,Guallar E,Clark JM.Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis.Hepatology. 2011;54:1082-90
39. Mishra P,Younossi ZM.Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD).Am J Gastroenterol. 2007;102:2716-7
40. Schwenzer NF,Springer F,Schraml C,Stefan N,Machann J,Schick F.Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance.J Hepatol. 2009;51:433-45
41. Bohte AE,van Werven JR,Bipat S,Stoker J.The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis.Eur Radiol. 2011;21:87-97
42. Springer F,Machann J,Claussen CD,Schick F,Schwenzer NF.Liver fat content determined by magnetic resonance imaging and spectroscopy.World J Gastroenterol. 2010;16:1560-6
43. Noureddin M, Lam J, Peterson MR, Middleton M, Hamilton G, Le TA, Bettencourt R, Changchien C, Brenner DA, Sirlin C, Loomba R. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013;58:1930--40.
44. Reeder SB,Hu HH,Sirlin CB.Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration.J Magn Reson Imaging. 2012;36:1011-4
45. Tang A,Tan J,Sun M,Hamilton G,Bydder M,Wolfson T,Gamst AC,Middleton M,Brunt EM,Loomba R,Lavine JE,Schwimmer JB,Sirlin CB.Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis.Radiology. 2013;267:422-31
46. Noureddin M,Lam J,Peterson MR,Middleton M,Hamilton G,Le TA,Bettencourt R,Changchien C,Brenner DA,Sirlin C,Loomba R.Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials.Hepatology. 2013;58:1930-40
47. Castera L,Vilgrain V,Angulo P.Noninvasive evaluation of NAFLD.Nat Rev Gastroenterol Hepatol. 2013;10:666-75
48. Barr J,Vazquez-Chantada M,Alonso C,Perez-Cormenzana M,Mayo R,Galan A,Caballeria J,Martin-Duce A,Tran A,Wagner C,Luka Z,Lu SC,Castro A,Le Marchand-Brustel Y,Martinez-Chantar ML,Veyrie N,Clement K,Tordjman J,Gual P,Mato JM.Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease.J Proteome Res. 2010;9:4501-12
49. Barr J,Caballeria J,Martinez-Arranz I,Dominguez-Diez A,Alonso C,Muntane J,Perez-Cormenzana M,Garcia-Monzon C,Mayo R,Martin-Duce A,Romero-Gomez M,Lo Iacono O,Tordjman J,Andrade RJ,Perez-Carreras M,Le Marchand-Brustel Y,Tran A,Fernandez-Escalante C,Arevalo E,Garcia-Unzueta M,Clement K,Crespo J,Gual P,Gomez-Fleitas M,Martinez-Chantar ML,Castro A,Lu SC,Vazquez-Chantada M,Mato JM.Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression.J Proteome Res. 2012;11:2521-32
50. Loomba R,Lutchman G,Kleiner DE,Ricks M,Feld JJ,Borg BB,Modi A,Nagabhyru P,Sumner AE,Liang TJ,Hoofnagle JH.Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.Aliment Pharmacol Therapeut. 2009;29:172-82
51. Lavine JE,Schwimmer JB,Van Natta ML,Molleston JP,Murray KF,Rosenthal P,Abrams SH,Scheimann AO,Sanyal AJ,Chalasani N,Tonascia J,Unalp A,Clark JM,Brunt EM,Kleiner DE,Hoofnagle JH,Robuck PR,Nonalcoholic Steatohepatitis Clinical Research N.Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.JAMA: J Am Med Assoc. 2011;305:1659-68
52. Assy N,Hussein O,Abassi Z.Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis.Gut. 2007;56:443-4
53. Harrison SA,Fecht W,Brunt EM,Neuschwander-Tetri BA.Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial.Hepatology. 2009;49:80-6
54. Van Wagner LB,Koppe SW,Brunt EM,Gottstein J,Gardikiotes K,Green RM,Rinella ME.Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial.Ann Hepatol. 2011;10:277-86
55. Zein CO,Yerian LM,Gogate P,Lopez R,Kirwan JP,Feldstein AE,McCullough AJ.Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.Hepatology. 2011;54:1610-9
56. Sanyal AJ,Chalasani N,Kowdley KV,McCullough A,Diehl AM,Bass NM,Neuschwander-Tetri BA,Lavine JE,Tonascia J,Unalp A,Van Natta M,Clark J,Brunt EM,Kleiner DE,Hoofnagle JH,Robuck PR,Nash CRN.Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.N Eng J Med. 2010;362:1675-85
57. Lindor KD,Kowdley KV,Heathcote EJ,Harrison ME,Jorgensen R,Angulo P,Lymp JF,Burgart L,Colin P.Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.Hepatology. 2004;39:770-8
58. Ratziu V,de Ledinghen V,Oberti F,Mathurin P,Wartelle-Bladou C,Renou C,Sogni P,Maynard M,Larrey D,Serfaty L,Bonnefont-Rousselot D,Bastard JP,Riviere M,Spenard J,FRESGUN.A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.J Hepatol. 2011;54:1011-9
59. Leuschner UF,Lindenthal B,Herrmann G,Arnold JC,Rossle M,Cordes HJ,Zeuzem S,Hein J,Berg T,Group NS.High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial.Hepatology. 2010;52:472-9
60. Li Y,Liu L,Wang B,Wang J,Chen D.Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis.Biomed Rep. 2013;1:57-64
61. Zein CO,Lopez R,Fu X,Kirwan JP,Yerian LM,McCullough AJ,Hazen SL,Feldstein AE.Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism.Hepatology. 2012;56:1291-9
62. Mudaliar S,Henry RR,Sanyal AJ,Morrow L,Marschall HU,Kipnes M,Adorini L,Sciacca CI,Clopton P,Castelloe E,Dillon P,Pruzanski M,Shapiro D.Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.Gastroenterology. 2013;145:574-82 e1
63. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E, NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015;385:956--65.
64. Silveira MG,Lindor KD.Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis.Expert Opin Pharmacother. 2014;15:365-72
65. Mato JM,Martinez-Chantar ML,Lu SC.S-adenosylmethionine metabolism and liver disease.Ann Hepatol. 2013;12:183-9
66. Lu SC,Mato JM.S-adenosylmethionine in liver health, injury, and cancer.Physiol Rev. 2012;92:1515-42
67. Mato JM,Lu SC.Role of S-adenosyl-L-methionine in liver health and injury.Hepatology. 2007;45:1306-12
68. Friedel HA,Goa KL,Benfield P.S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism.Drugs. 1989;38:389-416
69. Bottiglieri T.S-Adenosyl-L-methionine (SAMe): from the bench to the bedside—molecular basis of a pleiotrophic molecule.Am J Clin Nutr. 2002;76:1151S-7S
70. Li Z,Agellon LB,Allen TM,Umeda M,Jewell L,Mason A,Vance DE.The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis.Cell Metab. 2006;3:321-31
71. Duce AM,Ortiz P,Cabrero C,Mato JM.S-adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis.Hepatology. 1988;8:65-8
72. Lee TD,Sadda MR,Mendler MH,Bottiglieri T,Kanel G,Mato JM,Lu SC.Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis.Alcohol Clin Exp Res. 2004;28:173-81
73. Vendemiale G,Altomare E,Trizio T,Le Grazie C,Di Padova C,Salerno MT,Carrieri V,Albano O.Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease.Scand J Gastroenterol. 1989;24:407-15
74. Anstee QM,Day CP.S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility.J Hepatol. 2012;57:1097-109
75. Frezza M,Centini G,Cammareri G,Le Grazie C,Di Padova C.S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial.Hepato-gastroenterology. 1990;37:122-5
76. Qin B,Guo S,Zhao Y,Zou S,Zhang Q,Wang Z,Zeng W,Zhang D.A trial of ademetionine in the treatment of intrahepatic biliary stasis viral hepatitis.Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chin J Hepatol. 2000;8:158-60
77. Hardy ML, Coulter I, Morton SC, Favreau J, Venuturupalli S, Chiappelli F, Rossi F, Orshansky G, Jungvig LK, Roth EA, Suttorp MJ, Shekelle P. S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Evid Rep Technol Assess (Summ) 2003;64:1--3.
78. Ahmed KT,Almashhrawi AA,Rahman RN,Hammoud GM,Ibdah JA.Liver diseases in pregnancy: diseases unique to pregnancy.World J Gastroenterol: WJG. 2013;19:7639-46
79. Floreani A,Paternoster D,Melis A,Grella PV.S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial.Eur J Obstetr Gynecol Reproduct Biol. 1996;67:109-13
80. Frezza M,Pozzato G,Chiesa L,Stramentinoli G,di Padova C.Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine administration.Hepatology. 1984;4:274-8
81. Nicastri PL,Diaferia A,Tartagni M,Loizzi P,Fanelli M.A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy.Br J Obstetr Gynaecol. 1998;105:1205-7
82. Ribalta J,Reyes H,Gonzalez MC,Iglesias J,Arrese M,Poniachik J,Molina C,Segovia N.S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results.Hepatology. 1991;13:1084-9
83. Roncaglia N,Locatelli A,Arreghini A,Assi F,Cameroni I,Pezzullo JC,Ghidini A.A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis.BJOG: Int J Obstetr Gynaecol. 2004;111:17-21
84. Gurung V,Middleton P,Milan SJ,Hague W.Thornton JG. Interventions for treating cholestasis in pregnancy.Cochr Database Syst Rev. 2013;6:CD000493-CD000493
85. Song Z,Zhou Z,Chen T,Hill D,Kang J,Barve S,McClain C.S-adenosylmethionine (SAMe) protects against acute alcohol induced hepatotoxicity in mice.J Nutr Biochem. 2003;14:591-7
86. Colell A,Garcia-Ruiz C,Morales A,Ballesta A,Ookhtens M,Rodes J,Kaplowitz N,Fernandez-Checa JC.Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol-treated rats: effect of membrane physical properties and S-adenosyl-L-methionine.Hepatology. 1997;26:699-708
87. Medici V,Virata MC,Peerson JM,Stabler SP,French SW,Gregory JF,Albanese A,Bowlus CL,Devaraj S,Panacek EA,Richards JR,Halsted CH.S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial.Alcohol Clin Exp Res. 2011;35:1960-5
88. Trespi E,Panizza P,Colla C,Bottani G,De Vecchi P,Matti C.Efficacy of low dose mesalazine (5-ASA) in the treatment of acute inflammation and prevention of complications in patients with symptomatic diverticular disease.Preliminary results. Minerva gastroenterologica e dietologica. 1997;43:157-62
89. Mato JM,Camara J,Fernandez de Paz J,Caballeria L,Coll S,Caballero A,Garcia-Buey L,Beltran J,Benita V,Caballeria J,Sola R,Moreno-Otero R,Barrao F,Martin-Duce A,Correa JA,Pares A,Barrao E,Garcia-Magaz I,Puerta JL,Moreno J,Boissard G,Ortiz P,Rodes J.S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial.J Hepatol. 1999;30:1081-9
90. Rambaldi A,Gluud C.S-adenosyl-L-methionine for alcoholic liver diseases.Cochr Database Syst Rev. 2006;2:CD002235-CD002235
91. Feld JJ,Modi AA,El-Diwany R,Rotman Y,Thomas E,Ahlenstiel G,Titerence R,Koh C,Cherepanov V,Heller T,Ghany MG,Park Y,Hoofnagle JH,Liang TJ.S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders.Gastroenterology. 2011;140:830-9
92. Cano A,Buque X,Martinez-Una M,Aurrekoetxea I,Menor A,Garcia-Rodriguez JL,Lu SC,Martinez-Chantar ML,Mato JM,Ochoa B,Aspichueta P.Methionine adenosyltransferase 1A gene deletion disrupts hepatic very low-density lipoprotein assembly in mice.Hepatology. 2011;54:1975-86
93. Walker AK,Jacobs RL,Watts JL,Rottiers V,Jiang K,Finnegan DM,Shioda T,Hansen M,Yang F,Niebergall LJ,Vance DE,Tzoneva M,Hart AC,Naar AM.A conserved SREBP-1/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans.Cell. 2011;147:840-52
94. Vance DE.Physiological roles of phosphatidylethanolamine N-methyltransferase.Biochim Biophys Acta. 2013;1831:626-32
95. Jacobs RL,Zhao Y,Koonen DP,Sletten T,Su B,Lingrell S,Cao G,Peake DA,Kuo MS,Proctor SD,Kennedy BP,Dyck JR,Vance DE.Impaired de novo choline synthesis explains why phosphatidylethanolamine N-methyltransferase-deficient mice are protected from diet-induced obesity.J Biol Chem. 2010;285:22403-13
96. Li ZZ,Berk M,McIntyre TM,Feldstein AE.Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase.J Biol Chem. 2009;284:5637-44
97. Caballero F,Fernandez A,Matias N,Martinez L,Fucho R,Elena M,Caballeria J,Morales A,Fernandez-Checa JC,Garcia-Ruiz C.Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione.J Biol Chem. 2010;285:18528-36
98. Chawla RK,Bonkovsky HL,Galambos JT.Biochemistry and pharmacology of S-adenosyl-L-methionine and rationale for its use in liver disease.Drugs. 1990;40:98-110
99. Fu S,Yang L,Li P,Hofmann O,Dicker L,Hide W,Lin X,Watkins SM,Ivanov AR,Hotamisligil GS.Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity.Nature. 2011;473:528-31
100. Gomez-Santos L,Luka Z,Wagner C,Fernandez-Alvarez S,Lu SC,Mato JM,Martinez-Chantar ML,Beraza N.Inhibition of natural killer cells protects the liver against acute injury in the absence of glycine N-methyltransferase.Hepatology. 2012;56:747-59
101. Martinez-Una M,Varela-Rey M,Cano A,Fernandez-Ares L,Beraza N,Aurrekoetxea I,Martinez-Arranz I,Garcia-Rodriguez JL,Buque X,Mestre D,Luka Z,Wagner C,Alonso C,Finnell RH,Lu SC,Martinez-Chantar ML,Aspichueta P,Mato JM.Excess S-adenosylmethionine reroutes phosphatidylethanolamine towards phosphatidylcholine and triglyceride synthesis.Hepatology. 2013;58:1296-305
102. Puri P,Baillie RA,Wiest MM,Mirshahi F,Choudhury J,Cheung O,Sargeant C,Contos MJ,Sanyal AJ.A lipidomic analysis of nonalcoholic fatty liver disease.Hepatology. 2007;46:1081-90
103. Fujita K,Nozaki Y,Wada K,Yoneda M,Fujimoto Y,Fujitake M,Endo H,Takahashi H,Inamori M,Kobayashi N,Kirikoshi H,Kubota K,Saito S,Nakajima A.Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis.Hepatology. 2009;50:772-80
104. Murphy SK,Yang H,Moylan CA,Pang H,Dellinger A,Abdelmalek MF,Garrett ME,Ashley-Koch A,Suzuki A,Tillmann HL,Hauser MA,Diehl AM.Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease.Gastroenterology. 2013;145:1076-87
105. Moylan CA,Pang H,Dellinger A,Suzuki A,Garrett ME,Guy CD,Murphy SK,Ashley-Koch AE,Choi SS,Michelotti GA,Hampton DD,Chen Y,Tillmann HL,Hauser MA,Abdelmalek MF,Diehl AM.Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease.Hepatology. 2014;59:471-82
106. Kalhan SC,Edmison J,Marczewski S,Dasarathy S,Gruca LL,Bennett C,Duenas C,Lopez R.Methionine and protein metabolism in non-alcoholic steatohepatitis: evidence for lower rate of transmethylation of methionine.Clin Sci (Lond). 2011;121:179-89
107. Abdelmalek MF,Angulo P,Jorgensen RA,Sylvestre PB,Lindor KD.Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study.Am J Gastroenterol. 2001;96:2711-17
108. Abdelmalek MF,Sanderson SO,Angulo P,Soldevila-Pico C,Liu C,Peter J,Keach J,Cave M,Chen T,McClain CJ,Lindor KD.Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial.Hepatology. 2009;50:1818-26
109. Oz HS,Im HJ,Chen TS,de Villiers WJ,McClain CJ.Glutathione-enhancing agents protect against steatohepatitis in a dietary model.J Biochem Mol Toxicol. 2006;20:39-47
110. Chawla RK,Watson WH,Eastin CE,Lee EY,Schmidt J,McClain CJ.S-adenosylmethionine deficiency and TNF-alpha in lipopolysaccharide-induced hepatic injury.Am J Physiol. 1998;275:G125-9
111. Lu SC,Ramani K,Ou X,Lin M,Yu V,Ko K,Park R,Bottiglieri T,Tsukamoto H,Kanel G,French SW,Mato JM,Moats R,Grant E.S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model.Hepatology. 2009;50:462-71